NCT01205893
Completed
Phase 2
Study to Confirm the Safety and Efficacy of the Reducer on Patients With Refractory Angina
ConditionsRefractory Angina
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Refractory Angina
- Sponsor
- Neovasc Inc.
- Enrollment
- 104
- Locations
- 11
- Primary Endpoint
- Canadian Cardiovascular Society Angina Score
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to determine if the Reducer is safe and effective in treating the symptoms of refractory angina in patients that suffer from refractory angina who demonstrate reversible ischemia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient is older than 18 years of age
- •Symptomatic CAD with chronic refractory angina pectoris classified as Canadian Cardiovascular Society grade III or IV despite attempted optimal medical therapy for thirty days prior to screening
- •Patient has limited treatment options for revascularization by coronary artery bypass grafting or by percutaneous coronary intervention
- •Evidence of reversible ischemia that is attributable to the left coronary arterial system by Dobutamine Echo
- •Left ventricular ejection fraction greater than 25%
- •Male or non-pregnant female (NB: Females of child bearing potential must have a negative pregnancy test)
- •Patient understands the nature of the procedure and provides written informed consent prior to enrollment
- •Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
Exclusion Criteria
- •Recent (within three months) acute coronary syndrome
- •Recent (within six months) successful PCI or CABG
- •Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the thirty days prior to screening
- •De-compensated congestive heart failure (CHF) or hospitalization due to CHF during the three months prior to screening
- •Life threatening rhythm disorders or any rhythm disorders that would require placement of an internal defibrillator and or pacemaker
- •Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second that is less than 55% of the predicted value
- •Patient cannot undergo exercise tolerance test (bicycle) for reasons other than refractory angina
- •Severe valvular heart disease
- •Patient with pacemaker or defibrillator electrode in the right atrium, right ventricle, or coronary sinus
- •Patient having undergone tricuspid valve replacement or repair
Outcomes
Primary Outcomes
Canadian Cardiovascular Society Angina Score
Time Frame: 6 months
A decrease of two or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Secondary Outcomes
- Procedural success(24 hours)
- Periprocedural Serious Adverse Event:(30 days)
- Periprocedural Serious Adverse Event(30 days)
- Major Adverse Events(6 months)
- Canadian Cardiovascular Society Angina Score(6 months)
- Dobutamine Echo Wall Motion Score Index(6 months)
- Seattle Angina Questionnaire Score(6 months)
- Exercise Tolerance Testing(6 months)
- Technical success(24 hours)
Study Sites (11)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter StudyLeukemia, Lymphocytic, Acute, AdultNCT06649422Shandong University36
Recruiting
Phase 1
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomaNCT04443010Philogen S.p.A.226
Unknown
Not Applicable
A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth DiseaseHand, Foot and Mouth DiseaseNCT01175915Jiangsu Kanion Pharmaceutical Co., Ltd360
Withdrawn
Phase 2
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal EncephalomyopathyMitochondrial DiseasesMetabolic DiseaseInborn Errors of MetabolismNCT03866954St George's, University of London
Completed
Phase 2
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian CancerOvarian NeoplasmsNCT00772863Sanofi37